R. Salazar

Molecular Biology · 2012–2020

A researcher in the Science corpus: 4 papers; trusts 1 researcher and is trusted by 0 researchers here, as inferred from the citation graph.

Subfields

Whom R. Salazar trusts

Their strongest outbound trust, strongest first, inferred from their citations.

  1. W. Kaelin (in Molecular Biology)

Papers from R. Salazar's perspective

Ordered by how strongly the researchers R. Salazar trusts endorse each paper. Same corpus, a different order for every researcher.

  1. Actual 10-year survival after resection of colorectal liver metastases defines cure. (Journal of Clinical Oncology)
  2. Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07. (Journal of Clinical Oncology)
  3. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. (New England Journal of Medicine)
  4. Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR (Nature)
  5. Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF-Mutated Colorectal Cancer (Journal of Clinical Oncology)
  6. PD-1 blockade in tumors with mismatch repair deficiency. (Journal of Clinical Oncology)
  7. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. (Journal of Clinical Oncology)
  8. Mutations of the BRAF gene in human cancer (Nature)
  9. Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome (Science)
  10. Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer. (Journal of Clinical Oncology)

Their papers